+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PCSK9 Antagonists Market - Global Forecast 2026-2032- Product Image
PCSK9 Antagonists Market - Global Forecast 2026-2032- Product Image
Sale

PCSK9 Antagonists Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6124158
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The PCSK9 Antagonists Market is projected to reach USD 7.76 Billion in 2026. It is expected to continue growing at a CAGR of 6.80%, reaching USD 11.44 Billion by 2032.

PCSK9 Antagonists: Executive Summary and Market Context

PCSK9 antagonists are a class of lipid-lowering therapies designed to increase hepatic clearance of low-density lipoprotein cholesterol by reducing PCSK9-mediated degradation of LDL receptors. Their clinical relevance is strongest in patients who require additional LDL-cholesterol reduction beyond lifestyle measures and standard therapies, including people with established atherosclerotic cardiovascular disease, familial hypercholesterolemia, or intolerance to some conventional treatments. Adoption is shaped by clinical evidence, treatment guidelines, reimbursement, administration requirements, and the need to improve long-term adherence.

Clinical Integration and Access Are Reshaping the PCSK9 Antagonist Landscape

The landscape is shifting from viewing PCSK9 antagonists as specialist-only options toward integrating them into broader cardiovascular-risk management pathways. Guideline updates, greater use of risk-based treatment algorithms, and recognition of residual LDL-cholesterol risk support earlier consideration for eligible patients. At the same time, access remains dependent on prior authorization, diagnostic confirmation, affordability, injection preferences, and continuity of follow-up. Evidence generation is increasingly focused on real-world persistence, outcomes in diverse populations, combination treatment, and practical delivery models.

Artificial Intelligence Is Improving Patient Identification, Adherence, and Evidence Generation

Artificial intelligence can strengthen the PCSK9 antagonist care pathway by identifying patients with persistently elevated LDL cholesterol, probable familial hypercholesterolemia, or gaps between guideline recommendations and prescribed therapy. Predictive tools may help clinicians prioritize outreach, while natural-language processing can extract relevant information from clinical records and support eligibility assessment. AI-enabled monitoring may also identify adherence barriers and missed administrations. However, these applications require representative data, transparent validation, privacy safeguards, clinical oversight, and careful management of algorithmic bias; AI should support rather than replace medical judgment.

Regional Insights: Access Models and Cardiovascular Priorities Differ Across Six Geographies

North America combines substantial cardiovascular disease burden with advanced specialty-care infrastructure, but payer controls and treatment authorization can influence access. Europe is guided by coordinated clinical standards alongside country-specific reimbursement and health-technology-assessment processes. Asia-Pacific presents strong opportunities for earlier detection and expanded lipid management, while access varies across highly developed and emerging systems. Latin America faces uneven diagnosis, affordability constraints, and specialist availability. The Middle East is investing in chronic-disease care and prevention, with access differing across national health systems. Africa has significant unmet need linked to diagnosis, affordability, supply continuity, and specialist capacity, making primary-care integration and scalable delivery especially important.

Group Insights: Economic and Political Blocs Shape Procurement and Care Delivery

ASEAN markets reflect varied regulatory systems, reimbursement capacity, and urban-rural access, favoring adaptable evidence and distribution strategies. BRICS countries combine large and diverse patient populations with differing healthcare financing, domestic manufacturing capabilities, and diagnostic infrastructure. The European Union benefits from shared scientific and regulatory frameworks, although reimbursement decisions remain nationally determined. G7 systems generally have mature cardiovascular guidelines and data infrastructure, but face pressure to demonstrate value and reduce administrative barriers. GCC countries often have concentrated healthcare investment and advanced tertiary services, while population diversity and prevention priorities remain important. NATO members span distinct health systems, yet many share interests in resilient supply chains, outcomes research, and chronic-disease preparedness.

Country Insights: National Guidelines, Reimbursement, and Diagnosis Drive Uptake

Australia emphasizes evidence-based cardiovascular prevention within a universal healthcare framework, while Brazil must address regional inequality and public-private differences in access. Canada’s decentralized provincial coverage creates variation in eligibility and reimbursement. China is expanding cardiovascular prevention capacity but continues to navigate affordability, regional disparities, and population-scale screening needs. France, Germany, Italy, Spain, and the United Kingdom combine established specialist care with country-specific assessment, prescribing, and reimbursement pathways. India faces a high cardiovascular burden alongside substantial variation in diagnosis, affordability, and continuity of care. Japan and South Korea have advanced clinical systems with aging populations and strong interest in prevention. Mexico confronts uneven access and a growing need for systematic lipid-risk identification. Russia’s care environment is influenced by regional infrastructure, procurement, and broader health-system constraints. In the United States, clinical eligibility, payer policy, prior authorization, and affordability materially affect treatment initiation and persistence.

Action Priorities for Leaders: Improve Eligibility, Access, Persistence, and Evidence

Industry leaders should align clinical development and education with guideline-defined LDL-cholesterol goals and clearly characterized high-risk populations. Practical priorities include supporting standardized lipid testing, improving identification of familial hypercholesterolemia, simplifying authorization workflows, and developing patient-centered administration and follow-up services. Evidence programs should measure adherence, persistence, cardiovascular outcomes, health equity, and performance across routine-care settings rather than relying only on controlled-trial populations. Regional strategies should be tailored to reimbursement structures and care capacity, while responsible AI adoption should include independent validation, explainability, cybersecurity, and human review.

Research Methodology: Evidence-Based Synthesis of Clinical, Policy, and Access Factors

This executive summary uses a structured qualitative synthesis focused on the clinical role and adoption conditions of PCSK9 antagonists. The framework considers peer-reviewed clinical evidence, treatment guidelines, regulatory and health-technology-assessment materials, reimbursement policies, public-health data, and documented healthcare-delivery factors. Regional, group, and country comparisons are interpreted through differences in cardiovascular burden, diagnostic capacity, care pathways, financing, and regulatory context. No market estimates, market shares, forecasts, or company-specific assessments are included. Findings should be updated as guidelines, coverage policies, safety evidence, and real-world outcomes evolve.

Conclusion: PCSK9 Antagonists Require Integrated, Equitable Cardiovascular Care

PCSK9 antagonists have a defined role in intensive LDL-cholesterol management for appropriately selected patients, particularly when risk remains elevated despite foundational therapy or when treatment limitations exist. Their broader clinical impact will depend less on pharmacology alone than on timely diagnosis, guideline implementation, reimbursement, patient support, and durable adherence. Leaders who connect evidence generation with practical access solutions-and who apply AI responsibly to identify need and improve follow-up-will be better positioned to strengthen cardiovascular prevention across diverse health systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. PCSK9 Antagonists Market, by Dosage Form
7.1. Introduction
7.2. Prefilled Pen
7.3. Prefilled Syringe
7.4. Vial
8. PCSK9 Antagonists Market, by Molecule
8.1. Introduction
8.2. Alirocumab
8.3. Evolocumab
8.4. Inclisiran
9. PCSK9 Antagonists Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. PCSK9 Antagonists Market, by Application
10.1. Introduction
10.2. Atherosclerotic Cardiovascular Disease
10.2.1. Acute Coronary Syndrome
10.2.2. Stable Angina Pectoris
10.2.3. Stroke Prevention
10.3. Heterozygous Familial Hypercholesterolemia
10.4. Homozygous Familial Hypercholesterolemia
11. PCSK9 Antagonists Market, by End User
11.1. Introduction
11.2. Homecare Settings
11.3. Hospitals
11.4. Specialty Clinics
12. PCSK9 Antagonists Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. PCSK9 Antagonists Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. PCSK9 Antagonists Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Alnylam Pharmaceuticals, Inc.
16.2. Amgen Inc.
16.3. AstraZeneca PLC
16.4. CiVi Biopharma, Inc.
16.5. Daiichi Sankyo Company, Limited
16.6. Eli Lilly and Company
16.7. F. Hoffmann-La Roche Ltd
16.8. Innovent Biologics, Inc.
16.9. Ionis Pharmaceuticals, Inc.
16.10. Jiangsu Hengrui Medicine Co., Ltd.
16.11. LIB Therapeutics, Inc.
16.12. Merck & Co., Inc.
16.13. Novartis International AG
16.14. Pfizer Inc.
16.15. Regeneron Pharmaceuticals, Inc.
16.16. Sanofi S.A.
16.17. Shanghai Junshi Biosciences Co., Ltd.
16.18. Verve Therapeutics, Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global PCSK9 Antagonists Market, Years Considered for the Study
FIGURE 2. Global PCSK9 Antagonists Market, Research Design
FIGURE 3. Global PCSK9 Antagonists Market, Research Framework
FIGURE 4. Global PCSK9 Antagonists Market, Data Triangulation
FIGURE 5. Global PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
FIGURE 6. Global PCSK9 Antagonists Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 7. Global PCSK9 Antagonists Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global PCSK9 Antagonists Market Size, by Molecule, 2025 vs 2032 (%)
FIGURE 9. Global PCSK9 Antagonists Market Size, by Molecule, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global PCSK9 Antagonists Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global PCSK9 Antagonists Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global PCSK9 Antagonists Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global PCSK9 Antagonists Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global PCSK9 Antagonists Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global PCSK9 Antagonists Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global PCSK9 Antagonists Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global PCSK9 Antagonists Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global PCSK9 Antagonists Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global PCSK9 Antagonists Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global PCSK9 Antagonists Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global PCSK9 Antagonists Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global PCSK9 Antagonists Market Segmentation & Coverage
TABLE 2. Global PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 3. Global PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 4. Global Prefilled Pen Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Prefilled Pen Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Prefilled Pen Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 14. Global Alirocumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Alirocumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Alirocumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Evolocumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Evolocumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Evolocumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Inclisiran Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Inclisiran Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Inclisiran Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 24. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 34. Global Atherosclerotic Cardiovascular Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Atherosclerotic Cardiovascular Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Atherosclerotic Cardiovascular Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Acute Coronary Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Acute Coronary Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Acute Coronary Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Stable Angina Pectoris Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Stable Angina Pectoris Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Stable Angina Pectoris Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Stroke Prevention Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Stroke Prevention Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Stroke Prevention Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Heterozygous Familial Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Heterozygous Familial Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Heterozygous Familial Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Homozygous Familial Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Homozygous Familial Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Homozygous Familial Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global PCSK9 Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific PCSK9 Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 70. North America PCSK9 Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. North America PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 72. North America PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 73. North America PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. North America PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 75. North America PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 76. North America PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. Latin America PCSK9 Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Latin America PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 79. Latin America PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 80. Latin America PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 81. Latin America PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 82. Latin America PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 83. Latin America PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. Europe PCSK9 Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Europe PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 86. Europe PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 87. Europe PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Europe PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 89. Europe PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 90. Europe PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Middle East PCSK9 Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Middle East PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 93. Middle East PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 94. Middle East PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. Middle East PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 96. Middle East PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 97. Middle East PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. Africa PCSK9 Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Africa PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 100. Africa PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 101. Africa PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. Africa PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 103. Africa PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 104. Africa PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Global PCSK9 Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. ASEAN PCSK9 Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. ASEAN PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 108. ASEAN PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 109. ASEAN PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. ASEAN PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 111. ASEAN PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 112. ASEAN PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. GCC PCSK9 Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. GCC PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 115. GCC PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 116. GCC PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. GCC PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 118. GCC PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 119. GCC PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. European Union PCSK9 Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. European Union PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 122. European Union PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 123. European Union PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. European Union PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 125. European Union PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 126. European Union PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. BRICS PCSK9 Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. BRICS PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 129. BRICS PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 130. BRICS PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. BRICS PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 132. BRICS PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 133. BRICS PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. G7 PCSK9 Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. G7 PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 136. G7 PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 137. G7 PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. G7 PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 139. G7 PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 140. G7 PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. NATO PCSK9 Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. NATO PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 143. NATO PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 144. NATO PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. NATO PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 146. NATO PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 147. NATO PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Global PCSK9 Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. United States PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 150. United States PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 151. United States PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 152. United States PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. United States PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 154. United States PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 155. United States PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. Canada PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 157. Canada PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 158. Canada PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 159. Canada PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Canada PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. Canada PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 162. Canada PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. Mexico PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 164. Mexico PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 165. Mexico PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 166. Mexico PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Mexico PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 168. Mexico PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 169. Mexico PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. Brazil PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 171. Brazil PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 172. Brazil PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 173. Brazil PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. Brazil PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 175. Brazil PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 176. Brazil PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. United Kingdom PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 178. United Kingdom PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 179. United Kingdom PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 180. United Kingdom PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. United Kingdom PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 182. United Kingdom PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 183. United Kingdom PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Germany PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 185. Germany PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 186. Germany PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 187. Germany PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. Germany PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 189. Germany PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 190. Germany PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. France PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 192. France PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 193. France PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 194. France PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. France PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 196. France PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 197. France PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 198. Russia PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 199. Russia PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 200. Russia PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 201. Russia PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. Russia PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 203. Russia PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 204. Russia PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Italy PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 206. Italy PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 207. Italy PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 208. Italy PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. Italy PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 210. Italy PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 211. Italy PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. Spain PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 213. Spain PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 214. Spain PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 215. Spain PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. Spain PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 217. Spain PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 218. Spain PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. China PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 220. China PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 221. China PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 222. China PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. China PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 224. China PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 225. China PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. India PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 227. India PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 228. India PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 229. India PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. India PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 231. India PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 232. India PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. Japan PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 234. Japan PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 235. Japan PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 236. Japan PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. Japan PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 238. Japan PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 239. Japan PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. Australia PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 241. Australia PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 242. Australia PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 243. Australia PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Australia PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 245. Australia PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 246. Australia PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. South Korea PCSK9 Antagonists Market Size, 2017-2032 (USD Million)
TABLE 248. South Korea PCSK9 Antagonists Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 249. South Korea PCSK9 Antagonists Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 250. South Korea PCSK9 Antagonists Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. South Korea PCSK9 Antagonists Market Size, by Application, 2017-2032 (USD Million)
TABLE 252. South Korea PCSK9 Antagonists Market Size, by Atherosclerotic Cardiovascular Disease, 2017-2032 (USD Million)
TABLE 253. South Korea PCSK9 Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. Global PCSK9 Antagonists Market Share, by Key Player, 2025
TABLE 255. Global PCSK9 Antagonists Market, Key Experts

Companies Mentioned

  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • CiVi Biopharma, Inc.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Innovent Biologics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • LIB Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Verve Therapeutics, Inc.

Related Topics

Related Reports

Cholesterol Lowering Drug Market - Global Forecast 2026-2032 - Product Image

Cholesterol Lowering Drug Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
PCSK9 Inhibitor Market Report 2026 - Product Image

PCSK9 Inhibitor Market Report 2026

  • Report
  • 250 Pages
  • Global
From
PCSK9 Inhibitor Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2026 To 2034 - Product Image

PCSK9 Inhibitor Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2026 To 2034

  • Report
  • 179 Pages
  • Global
From
Fibrate Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Fibrate Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 130 Pages
  • Global
From
Hyperlipidemia Drugs Market - Global Forecast 2026-2032 - Product Image

Hyperlipidemia Drugs Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.